Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cardiothoracic Surgery
Published in: Journal of Cardiothoracic Surgery 1/2024

Open Access 01-12-2024 | Celecoxib | Research

Cardioprotective role of royal jelly in the prevention of celecoxib-mediated cardiotoxicity in adult male albino rats

Authors: Naglaa Z. H. Eleiwa, Hesham A. M. I. Khalifa, Heba A. Nazim

Published in: Journal of Cardiothoracic Surgery | Issue 1/2024

Login to get access

Abstract

Background

Celecoxib, a cyclooxygenase-2 selective inhibitor non-steroidal anti-inflammatory drugs, is used for the management of short- and long-term pain as well as in other inflammatory conditions. Unfortunately, its chronic use is highly associated with serious abnormal cardiovascular events. The current study was designed to explore the effect of long-term administration of celecoxib on the cardiac tissues of male albino rats. The study also examined the alleged cardioprotective effect of royal jelly.

Methods

Thirty, male albino rats were randomly divided into 3 equal groups; 10 each: (1) rats served as the control group and received no drug; (2) rats received celecoxib (50 mg/kg/day, orally), for 30 consecutive days; (3) rats received celecoxib (50 mg/kg/day, orally) plus royal jelly (300 mg/kg/day, orally) for 30 consecutive days. Sera were collected to assay cardiac enzymes and oxidant/antioxidant status. Rats were euthanatized and cardiac tissues were dissected for quantitative estimation of apoptotic genes (Bax) and anti-apoptotic gene (Bcl-2).

Results

Long-term celecoxib administration caused cardiotoxicity in male albino rats as manifested by significant elevation of serum levels of creatine phosphokinase (CPK), creatine kinase-MB (CK-MB), and lactate dehydrogenase (LDH), with ameliorative effects of royal jelly against celecoxib-induced cardiotoxicity as manifested by significantly decrease in serum CPK, CK-MB, and LDH levels. It also showed a significant decrease in the oxidative stress indicator malondialdehyde (MDA) levels and the bax gene. Additionally, it demonstrated significant increases in the bcl-2 gene and superoxide dismutase (SOD) levels, which contribute to its therapeutic effects against celecoxib-induced cardiotoxicity.

Conclusion

Long-term celecoxib administration caused cardiotoxicity in male albino rats with protective effect of royal jelly being given together. It could be concluded that royal jelly may prove a useful adjunct in patients being prescribed celecoxib.

Trial registration

Not applicable.
Literature
1.
Clemett D, Goa KL. Celecoxib: a review of its use in osteoarthritis, rheumatoid arthritis and acute pain. Drugs. 2000;59:957–80.PubMedCrossRef
2.
McCormack PL. Celecoxib: a review of its use for symptomatic relief in the treatment of osteoarthritis, rheumatoid arthritis and ankylosing spondylitis. Drugs. 2011;71:2457–89.PubMedCrossRef
3.
Caldwell B, Aldington S, Weatherall M, Shirtcliffe P, Beasley R. Risk of cardiovascular events and celecoxib: a systematic review and meta-analysis. J R Soc Med. 2006;99(3):132–40.PubMedPubMedCentralCrossRef
4.
Puljak L, Marin A, Vrdoljak D, Markotic F, Utrobicic A, Tugwell P. Celecoxib for osteoarthritis. Cochrane Database Syst Reviews. 2017(5).
5.
Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Investig. 2006;116(1):4–15.PubMedPubMedCentralCrossRef
6.
Cruz JV, Rosa JM, Kimani NM, Giuliatti S, dos Santos CB. The role of celecoxib as a potential inhibitor in the treatment of inflammatory diseases review. Curr Med Chem. 2022;29(17):3028–49.PubMedCrossRef
7.
Cryer B. The role of cyclooxygenase selective inhibitors in the gastrointestinal tract. Curr Gastroenterol Rep. 2003;5(6):453–8.PubMedCrossRef
8.
Ahmad S, Campos MG, Fratini F, Altaye SZ, Li J. New insights into the biological and pharmaceutical properties of royal jelly. Int J Mol Sci. 2020;21(2):382.PubMedPubMedCentralCrossRef
9.
Mostafa RE, El-Marasy SA, Jaleel GA, Bakeer RM. Protective effect of royal jelly against diclofenac-induced hepato-renal damage and gastrointestinal ulcerations in rats. Heliyon. 2020; 6(2).
10.
Malekinejad H, Ahsan S, Delkhosh-Kasmaie F, Cheraghi H, Rezaei-Golmisheh A, Janbaz-Acyabar H. Cardioprotective effect of royal jelly on paclitaxel-induced cardio-toxicity in rats. Iran J Basic Med Sci. 2016;19(2):221.PubMedPubMedCentral
11.
Sarhan H, Naoum L. Protective role of royal jelly against gamma radiation-induced oxidative stress, cardio-toxicity, and organ dysfunctions in male rats. Egypt J Hosp Med. 2020;78(1):62–7.CrossRef
12.
Sargazi M, Taghian F. Royal Jelly bioactive compounds and exercise improved cardiomyopathy and redox status in patients under methadone maintenance therapy: randomized clinical trial. J Herb Med. 2023;38:100634.CrossRef
13.
Koçkaya EA, Selmanoğlu G, Kısmet K, Akay MT. Pathological and biochemical effects of therapeutic and supratherapeutic doses of celecoxib in Wistar albino male rats. Drug Chem Toxicol. 2010;33(4):410–4.PubMedCrossRef
14.
Eleawa SM, Alkhateeb MA, Alhashem FH, Bin-Jaliah I, Sakr HF, Elrefaey HM, et al. Resveratrol reverses cadmium chloride-induced testicular damage and subfertility by downregulating p53 and Bax and upregulating gonadotropins and Bcl-2 gene expression. J Reprod Dev. 2014;60(2):115–27.PubMedPubMedCentralCrossRef
15.
Wang M, Utell MJ, Schneider A, Zareba W, Frampton MW, Oakes D, Hopke PK, Wiltshire J, Kane C, Peters A, Breitner S. Does total antioxidant capacity modify adverse cardiac responses associated with ambient ultrafine, accumulation mode, and fine particles in patients undergoing cardiac rehabilitation? Environ Res. 2016;149:15–22.PubMedPubMedCentralCrossRef
16.
Montinari MR, Minelli S, De Caterina R. The first 3500 years of aspirin history from its roots–A concise summary. Vascul Pharmacol. 2019;113:1–8.PubMedCrossRef
17.
Maruyama R, Kiyohara Y, Kudo Y, Sugiyama T. Effects of the anti-inflammatory drug celecoxib on cell death signaling in human colon cancer. Naunyn Schmiedebergs Arch Pharmacol. 2023;24:1–5.
18.
Andersohn F, Suissa S, Garbe E. Use of first-and second-generation cyclooxygenase-2–selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation. 2006;113(16):1950–7.PubMedCrossRef
19.
Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. JAMA. 2000;284(10):1247–55.PubMedCrossRef
20.
Solomon DH, Schneeweiss S, Glynn RJ, Kiyota Y, Levin R, Mogun H, Avorn J. Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation. 2004;109(17):2068–73.PubMedCrossRef
21.
Farkouh ME, Kirshner H, Harrington RA, Ruland S, Verheugt FW, Schnitzer TJ, et al. Comparison of lumiracoxib with naproxen and ibuprofen in the therapeutic Arthritis Research and gastrointestinal event trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet. 2004;364(9435):675–84.PubMedCrossRef
22.
Solomon SD, McMurray JJ, Pfeffer MA, Wittes J, Fowler R, Finn P, et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071–80.PubMedCrossRef
23.
Chen W, Liang J, Fu Y, Jin Y, Yan R, Chi J et al. Cardioprotection of cortistatin against isoproterenol-induced myocardial injury in rats. Annals Translational Med. 2020; 8(6).
24.
Antman E, Bassand JP, Klein W, Ohman M, Lopez Sendon JL, Rydén L, et al. Myocardial infarction redefined—a consensus document of the Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction: the Joint European Society of Cardiology/American College of Cardiology Committee. J Am Coll Cardiol. 2000;36(3):959–69.PubMedCrossRef
25.
Farvin KS, Anandan R, Kumar SH, Shiny KS, Sankar TV, Thankappan TK. Effect of squalene on tissue defense system in isoproterenol-induced myocardial infarction in rats. Pharmacol Res. 2004;50(3):231–6.CrossRef
26.
Ahmad S, Panda BP, Kohli K, Fahim M, Dubey K. Folic acid ameliorates celecoxib cardiotoxicity in a doxorubicin heart failure rat model. Pharm Biol. 2017;55(1):1295–303.PubMedPubMedCentralCrossRef
27.
Mosaad SM, Zaitone SA, Ibrahim A, El-Baz AA, Abo-Elmatty DM, Moustafa YM. Celecoxib aggravates cardiac apoptosis in L-NAME-induced pressure overload model in rats: immunohistochemical determination of cardiac caspase-3, Mcl-1, Bax and Bcl-2. Chemico-Biol Interact. 2017;272:92–106.CrossRef
28.
Ahmad S, Panda BP, Fahim M, Dhyani N, Dubey K. Ameliorative effect of beraprost sodium on celecoxib induced cardiotoxicity in rats. Iran J Pharm Research: IJPR. 2018;17(1):155.PubMedPubMedCentral
29.
FitzGerald GA. COX-2 and beyond approaches to prostaglandin inhibition in human disease. Nat Rev Drug Discovery. 2003;2(11):879–90.PubMedCrossRef
30.
31.
Saini SS, Gessell-Lee DL, Peterson JW. The cox-2-specific inhibitor celecoxib inhibits adenylyl cyclase. Inflammation. 2003;27:79–88.PubMedCrossRef
32.
Rabausch K, Bretschneider E, Sarbia M, Meyer-Kirchrath J, Censarek P, Pape R, Fischer JW, Schrör K, Weber AA. Regulation of thrombomodulin expression in human vascular smooth muscle cells by COX-2–derived prostaglandins. Circul Res. 2005;96(1):e1–6.CrossRef
33.
Fosslien E. Cardiovascular complications of non-steroidal anti-inflammatory drugs. Annals Clin Lab Sci. 2005;35(4):347–85.
34.
Chu AJ. Tissue factor upregulation drives a thrombosis–inflammation circuit in relation to cardiovascular complications. Cell biochemistry and function: Cellular biochemistry and its modulation by active agents or disease. 2006; 24(2):173–92.
35.
Atashbar S, Jamali Z, Khezri S, Salimi A. Celecoxib decreases mitochondrial complex IV activity and induces oxidative stress in isolated rat heart mitochondria: an analysis for its cardiotoxic adverse effect. J Biochem Mol Toxicol. 2022;36(1):e22934.PubMedCrossRef
36.
Mair J, Artner-Dworzak E, Lechleitner P, Morass B, Smidt J. Wagner iet al. Early diagnosis of acute myocardial infarction by a newly developed rapid immunoturbidimetric assay for myoglobin. Heart. 1992;68(11):462–8.CrossRef
37.
Srikanth G, Prakash P, Tripathy N, Dikshit M, Nityanand S. Establishment of a rat model of myocardial infarction with a high survival rate: a suitable model for evaluation of efficacy of stem cell therapy. J Stem Cells Regenerative Med. 2009;5(1):30.CrossRef
38.
Goicoechea M, Cía F, José CS, Asensio A, Emparanza JI, Gil AG, et al. Minimizing creatine kinase variability in rats for neuromuscular research purposes. Lab Anim. 2008;42(1):19–25.PubMedCrossRef
39.
Silici S, Ekmekcioglu O, Kanbur M, Deniz K. The protective effect of royal jelly against cisplatin-induced renal oxidative stress in rats. World J Urol. 2011;29:127–32.PubMedCrossRef
40.
41.
Trevisan M, Browne R, Ram M, Muti P, Freudenheim J, Carosella AM, et al. Correlates of markers of oxidative status in the general population. Am J Epidemiol. 2001;154(4):348–56.PubMedCrossRef
42.
Bernabucci U, Ronchi B, Lacetera N, Nardone A. Markers of oxidative status in plasma and erythrocytes of transition dairy cows during hot season. J Dairy Sci. 2002;85(9):2173–9.PubMedCrossRef
43.
Rao PS, Kalva S, Yerramilli A, Mamidi S. Free radicals and tissue damage: role of antioxidants. Free Radicals Antioxid. 2011;1(4):2–7.CrossRef
44.
Dupré-Crochet S, Erard M, Nüβe O. ROS production in phagocytes: why, when, and where? J Leukoc Biol. 2013;94(4):657–70.PubMedCrossRef
45.
Valko M, Leibfritz D, Moncol J, Cronin MT, Mazur M, Telser J. Free radicals and antioxidants in normal physiological functions and human disease. Int J Biochem Cell Biol. 2007;39(1):44–84.PubMedCrossRef
46.
Pham-Huy LA, He H, Pham-Huy C. Free radicals, antioxidants in disease and health. Int J Biomedical Science: IJBS. 2008;4(2):89–96.CrossRef
47.
David AV, Arulmoli R, Parasuraman S. Overviews of biological importance of quercetin: a bioactive flavonoid. Pharmacogn Rev. 2016;10(20):84–6.CrossRef
48.
49.
Reiter RJ, Paredes SD, Manchester LC, Tan DX. Reducing oxidative/nitrosative stress: a newly-discovered genre for melatonin. Crit Rev Biochem Mol Biol. 2009;44(4):175–200.PubMedCrossRef
50.
Ziech D, Franco R, Georgakilas AG, Georgakila S, Malamou-Mitsi V, Schoneveld O, et al. The role of reactive oxygen species and oxidative stress in environmental carcinogenesis and biomarker development. Chemico-Biol Interact. 2010;188(2):334–9.CrossRef
51.
Mirończuk-Chodakowska I, Witkowska AM, Zujko ME. Endogenous non-enzymatic antioxidants in the human body. Adv Med Sci. 2018;63(1):68–78.PubMedCrossRef
52.
Burak Cimen MY, Bölgen Cimen Ö, Eskandari G, Sahin G, Erdoğan C, Atik U. In vivo effects of meloxicam, celecoxib, and ibuprofen on free radical metabolism in human erythrocytes. Drug Chem Toxicol. 2003;26(3):169–76.PubMedCrossRef
53.
Ozgocmen S, Ardicoglu O, Erdogan H, Fadillioglu E, Gudul H. In vivo effect of celecoxib and tenoxicam on oxidant/anti-oxidant status of patients with knee osteoarthritis. Annals Clin Lab Sci. 2005;35(2):137–43.
54.
Sozer S, Diniz G, Lermioglu F. Effects of celecoxib in young rats: histopathological changes in tissues and alterations of oxidative stress/antioxidant defense system. Arch Pharm Res. 2011;34:253–9.PubMedCrossRef
55.
Melekh B, Ilkiv I, Lozynskyi A, Sklyarov A. Antioxidant enzyme activity and lipid peroxidation in rat liver exposed to celecoxib and lansoprazole under epinephrine-induced stress. J Appl Pharm Sci. 2017;7(10):094–9.
56.
Hamza RZ, Al-Eisa RA, El-Shenawy NS. Possible ameliorative effects of the royal jelly on hepatotoxicity and oxidative stress induced by molybdenum nanoparticles and/or cadmium chloride in male rats. Biology. 2022;11(3):450.PubMedPubMedCentralCrossRef
57.
Cotter TG, Rinella M. Nonalcoholic fatty liver disease 2020: the state of the disease. Gastroenterology. 2020;158(7):1851–64.PubMedCrossRef
58.
You MM, Liu YC, Chen YF, Pan YM, Miao ZN, Shi YZ, Si JJ, Chen ML, Hu FL. Royal jelly attenuates nonalcoholic fatty liver disease by inhibiting oxidative stress and regulating the expression of circadian genes in ovariectomized rats. J Food Biochem. 2020;44(3):e13138.PubMedCrossRef
59.
Karimi E, Khorvash F, Arab A, Sepidarkish M, Saadatnia M, Amani R. The effects of royal jelly supplementation on oxidative stress, inflammatory mediators, mental health, cognitive function, quality of life, and clinical outcomes of patients with ischemic stroke: study protocol for a randomized controlled trial. BMC Nutr. 2023;9(1):1–8.CrossRef
60.
Kohno K, Okamoto I, Sano O, Arai N, Iwaki K, Ikeda M, Kurimoto M. Royal jelly inhibits the production of proinflammatory cytokines by activated macrophages. Biosci Biotechnol Biochem. 2004;68(1):138–45.PubMedCrossRef
61.
Aslan Z, Aksoy L. Anti-inflammatory effects of royal jelly on ethylene glycol induced renal inflammation in rats. Int Brazilian J Urol. 2015;41:1008–13.CrossRef
62.
Hadi A, Najafgholizadeh A, Aydenlu ES, Shafiei Z, Pirivand F, Golpour S, et al. Royal jelly is an effective and relatively safe alternative approach to blood lipid modulation: a meta-analysis. J Funct Foods. 2018;41:202–9.CrossRef
63.
Maleki V, Jafari-Vayghan H, Saleh-Ghadimi S, Adibian M, Kheirouri S, Alizadeh M. Effects of Royal jelly on metabolic variables in diabetes mellitus: a systematic review. Complement Ther Med. 2019;43:20–7.PubMedCrossRef
64.
Kanbur M, Eraslan G, Silici S, Karabacak M. Effects of sodium fluoride exposure on some biochemical parameters in mice: evaluation of the ameliorative effect of royal jelly applications on these parameters. Food Chem Toxicol. 2009;47(6):1184–9.PubMedCrossRef
65.
66.
Rathore S, Datta G, Kaur I, Malhotra P, Mohmmed A. Disruption of cellular homeostasis induces organelle stress and triggers apoptosis-like cell-death pathways in malaria parasite. Cell Death Dis. 2015;6(7):e1803.PubMedPubMedCentralCrossRef
67.
Hussar P. Apoptosis regulators bcl-2 and caspase-3. Encyclopedia. 2022;2(4):1624–36.CrossRef
68.
Lockshin RA, Zakeri Z. Programmed cell death and apoptosis: origins of the theory. Nat Rev Mol Cell Biol. 2001;2(7):545–450.PubMedCrossRef
69.
70.
Fink SL, Cookson BT. Apoptosis, pyroptosis, and necrosis: mechanistic description of dead and dying eukaryotic cells. Infect Immun. 2005;73(4):1907–16.PubMedPubMedCentralCrossRef
71.
72.
D’arcy MS. Cell death: a review of the major forms of apoptosis, necrosis and autophagy. Cell Biol Int. 2019;43(6):582–92.PubMedCrossRef
73.
74.
Shao D, Kan M, Qiao P, Pan Y, Wang Z, Xiao X, Li J, Chen L. Celecoxib induces apoptosis via a mitochondria-dependent pathway in the H22 mouse hepatoma cell line. Mol Med Rep. 2014;10(4):2093–8.PubMedCrossRef
75.
Choi SM, Cho YS, Park G, Lee SK, Chun KS. Celecoxib induces apoptosis through akt inhibition in 5-fluorouracil-resistant gastric cancer cells. Toxicol Res. 2021;37:25–33.PubMedCrossRef
76.
77.
Gao D, Nyalali AM, Hou Y, Xu Y, Zhou J, Zhao W, Huang B, Li F. 2, 5-Dimethyl celecoxib inhibits proliferation and cell cycle and induces apoptosis in glioblastoma by suppressing CIP2A/PP2A/Akt signaling Axis. J Mol Neurosci. 2021;1:1–11.
78.
Karadeniz A, Simsek N, Karakus E, Yildirim S, Kara A, Can I, Kisa F, Emre H, Turkeli M. Royal jelly modulates oxidative stress and apoptosis in liver and kidneys of rats treated with cisplatin. Oxidative medicine and cellular longevity. 2011; 2011.
79.
Azad F, Nejati V, Shalizar-Jalali A, Najafi G, Rahmani F. Antioxidant and anti‐apoptotic effects of royal jelly against nicotine‐induced testicular injury in mice. Environ Toxicol. 2019;34(6):708–18.PubMedCrossRef
80.
Mohamed HK, Mobasher MA, Ebiya RA, Hassen MT, Hagag HM, El-Sayed R, et al. Anti-inflammatory, anti-apoptotic, and antioxidant roles of honey, royal jelly, and propolis in suppressing nephrotoxicity induced by doxorubicin in male albino rats. Antioxidants. 2022;11(5):1029.PubMedPubMedCentralCrossRef
81.
Tohamy HG, El-Neweshy MS, Soliman MM, Sayed S, Shukry M, Ghamry HI, Abd-Ellatieff H. Protective potential of royal jelly against hydroxyurea-induced hepatic injury in rats via antioxidant, anti-inflammatory, and anti-apoptosis properties. PLoS ONE. 2022;17(3):e0265261.PubMedPubMedCentralCrossRef
82.
Fazili N, Soheili ZS, Malekzadeh-Shafaroudi S, Samiei S, D Alipoor S, Moshtaghi N, et al. Royal Jelly decreases MMP-9 expression and induces apoptosis in human bladder Cancer 5637 cells. J Cell Mol Res. 2021;13(1):36–43.
Metadata
Title
Cardioprotective role of royal jelly in the prevention of celecoxib-mediated cardiotoxicity in adult male albino rats
Authors
Naglaa Z. H. Eleiwa
Hesham A. M. I. Khalifa
Heba A. Nazim
Publication date
01-12-2024
Publisher
BioMed Central
Keyword
Celecoxib
Published in
Journal of Cardiothoracic Surgery / Issue 1/2024
Electronic ISSN: 1749-8090
DOI
https://doi.org/10.1186/s13019-024-02593-2

Other articles of this Issue 1/2024

Journal of Cardiothoracic Surgery 1/2024 Go to the issue

Case Report

18F-FDG PET/MR: a new imaging approach

Research

In a porcine model of implantable pacemakers for pediatric unilateral diaphragm paralysis, the phrenic nerve is the best target

Case Report

Myocardial infarction due to coronary embolism after mechanical aortic valve replacement: a case report

Case Report

Hemorrhagic pericardial tamponade in a hemodialysis patient with catheter-related superior vena cava syndrome: a case report

Case Report

Treatment of late left bronchopleural fistula after left pneumonectomy through right thoracic approach assisted by extracorporeal membrane oxygenation

Research

Experience with aortic arch inclusion technique using artificial blood vessel for type A aortic dissection: an application study